Do atypical antipsychotic drugs reduce the risk of ischemic heart disease and mortality? Possible role of 5-HT2A receptor blockade

Schizophrenia Research

Volumn 119, Issue 1-3, 2010, Pages 160-163

  Blasco Fontecilla, Hilario ^a   Baca Garcia, Enrique ^a,b   de Leon, Jose ^c  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b NewYork Presbyterian Hospital   (United States)

^c M Hlth Res Ctr at E State Hosp   (United States)

Author keywords

Adverse effects; Antipsychotics; Coronary artery disease; Long QT syndrome; Metabolic syndrome; Mortality; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HISTAMINE H1 RECEPTOR ANTAGONIST; N [2 [4 (5H DIBENZO[A,D]CYCLOHEPTEN 5 YLIDENE)PIPERIDINO]ETHYL] 1 FORMYLISONIPECOTAMIDE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; THIORIDAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ARTICLE; GLUCOSE METABOLISM; HEART DEATH; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MORTALITY; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SCHIZOPHRENIA; SMOKING CESSATION; THROMBOCYTE AGGREGATION INHIBITION; TORSADE DES POINTES; UPREGULATION; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CAUSE OF DEATH; HUMANS; LONG-TERM CARE; MYOCARDIAL ISCHEMIA; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, HISTAMINE H1; RISK; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 77952668659     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.12.005     Document Type: Article

References (43)

1. Arranz M.J., de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 2007, 12:707-747.
2. Daumit G.L., Goff D.C., Meyer J.M., Davis V.G., Nasrallah H.A., McEvoy J.P., Rosenheck R., Davis S.M., Hsiao J.K., Stroup T.S., Lieberman J.A. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr. Res. 2008, 105:175-187.
3. de Leon J. Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, and co-morbid substance use (editorial). J. Clin. Psychopharmacol. 2008, 28:125-131.
4. de Leon J., Diaz F.J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr. Res. 2005, 76:135-157.
5. de Leon J., Diaz F.J. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophr. Res. 2007, 96:185-197.
6. de Leon J., Diaz F.J., Josiassen R.C., Cooper T.B., Simpson G.M. Does clozapine decrease smoking?. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:757-762.
7. de Leon J., Diaz F.J., Aguilar M.C., Jurado D., Gurpegui M. Does smoking reduce akathisia?: Testing a narrow version of the self-medication hypothesis. Schizophr. Res. 2006, 86:256-268.
8. de Leon J., Gurpegui M., Diaz F.J. Epidemiology of comorbid tobacco use and schizophrenia: thinking about risks and protective factors. J. Dual Diag. 2007, 3:9-25.
9. de Leon J., Sandson N.B., Cozza K.L. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I. Psychosomatics 2008, 49:258-270.
10. de Leon J., Sandson N.B., Cozza K.L. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II. Psychosomatics 2008, 49:347-361.
11. Diaz F.J., Meary A., Arranz M.J., Ruaño G., Windemuth A., de Leon J. Acetyl-coenzyme A carboxylase ? gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels. Schizophr. Res. 2009, 115:136-140.
12. EMEA (European Medicines Agency), 2008. CHMP assessment report on conventional antipsychotics (EMEA/CHMP/590557/2008). http://www.emea.europa.eu/pdfs/human/opiniongen/Conventional_%20Antipsychotics_Article5.3-Appendix1-CHMPAR.pdf.
13. Goff D.C., Cather C., Evins A.E., Henderson D.C., Freudenreich O., Copeland P.M., Bierer M., Duckworth K., Sacks F.M. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J. Clin. Psychiatry 2005, 66:183-194.
14. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., Lamberti S., D'Agostino R.B., Stroup T.S., Davis S., Lieberman J.A. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 2005, 80:45-53.
15. Grover G.J., Sargent C.A., Dzwonczyk S., Normandin D.E., Antonaccio M.J. Protective effect of serotonin (5-HT2) receptor antagonists in ischemic rat hearts. J. Cardiovasc. Pharmacol. 1993, 22:664-672.
16. Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., Höschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20:389-409.
17. Joukamaa M., Heliovaara M., Knekt P., Aromaa A., Raitasalo R., Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br. J. Psychiatry 2006, 188:122-127.
18. Kihara H., Hirose K., Koganei H., Sasaki N., Yamamoto H., Kimura A., Nishimori T., Shoji M., Yoshimoto R. AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats. J. Cardiovasc. Pharmacol. 2000, 35:523-530.
19. Koponen H., Alaraisanen A., Saari K., Pelkonen O., Huikuri H., Raatikainen M.J., Savolainen M., Isohanni M. Schizophrenia and sudden cardiac death: a review. Nord. J. Psychiatry 2008, 62:342-345.
20. Lairez O., Calise D., Bianchi P., Ordener C., Spreux-Varoquaux O., Guilbeau-Frugier C., Escourrou G., Seif I., Roncalli J., Pizzinat N., Galinier M., Parini A., Mialet-Perez J. Genetic deletion of MAO-A promotes serotonin-dependent ventricular hypertrophy by pressure overload. J. Mol. Cell. Cardiol. 2009, 46:587-595.
21. Lieberman, J.A., Merrill, D., Parameswaran, S. (2009). APA guidance on the use of antipsychotic drugs and cardiac sudden death prepared by for the APA Council on Research. http://www.omh.state.ny.us/omhweb/advisories/adult_antipsychotic_use_attachement.html.
22. Matsui-Sakata A., Ohtani H., Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotic-induced weight gain and diabetes mellitus. Drug Metab. Pharmacokinet. 2005, 20:368-378.
23. Meyer J.M., Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 2004, 70:1-17.
24. Meyer J.M., Stahl S.M. The metabolic syndrome and schizophrenia. Acta Psychiatr. Scand. 2009, 119:4-14.
25. Meyer J.M., McEvoy J.P., Davis V.G., Goff D.C., Nasrallah H.A., Davis S.M., Hsiao J.K., Swartz M.S., Stroup T.S., Lieberman J.A. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. Biol. Psychiatry 2009, 66:1013-1022.
26. Michelsen J.W., Meyer J.M. Cardiovascular effects of antipsychotics. Expert Rev. Neurother. 2007, 7:829-839.
27. Montout C., Casadebaig F., Lagnaoui R., Verdoux H., Philippe A., Begaud B., Moore N. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr. Res. 2002, 57:147-156.
28. Muto T., Hotta Y., Miyazeki K., Ando H., Ishikawa N., Hasegawa T., Sugimoto Y., Yamada J., Miki Y. Protective effects of sarpogrelate, a 5-HT2A antagonist, against postischemic myocardial dysfunction in guinea-pig hearts. Mol. Cell. Biochem. 2005, 272:119-132.
29. Nagatomo T., Rashid M., Abul Muntasir H., Komiyama T. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol. Ther. 2004, 104:59-81.
30. Nasrallah H.A. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. J. Clin. Psychiatry 2007, 68(Suppl 1):5-11.
31. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry 2008, 13:27-35.
32. Nasrallah H.A., Meyer J.M., Goff D.C., McEvoy J.P., Davis S.M., Stroup T.S., Lieberman J.A. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr. Res. 2006, 86:15-22.
33. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
34. Ramos-Ríos R., Arrojo-Romero M., Paz Silva E., Fernández-Pérez R., Carballal-Calvo F., Bouzón-Barreiro J.L., Seoane-Prado J., Codesido-Barcala R., Crespí-Armenteros A., Fernández-Pérez R., López-Moríñigo J.L., Tortajada-Bonaselt I., Diaz F.J., de Leon J. QTc interval in a sample of long-term schizophrenia inpatients. Schizophr. Res. 2009, 116:35-43.
35. Ray W.A., Chung C.P., Murray K.T., Hall K., Stein C.M. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med. 2009, 360:225-235.
36. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry 2007, 64:1123-1131.
37. Schins A., Hamulyak K., Scharpe S., Lousberg R., Van Melle J., Crijns H., Honig A. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sci. 2004, 76:637-650.
38. Susce M.T., Villanueva N., Diaz F.J., de Leon J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J. Clin. Psychiatry 2005, 66:167-173.
39. Sweet R.A., Pollock B.G., Mulsant B.H., Rosen J., Sorisio D., Kirshner M., Henteleff R., DeMichele M.A. Pharmacologic profile of perphenazine's metabolites. J. Clin. Psychopharmacol. 2000, 20:181-187.
40. Tiihonen J., Lonnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374:620-627.
41. Villanueva N., Markham-Abedi C., McNeely C., Diaz F.J., de Leon J. Probable association between ziprasidone and worsening hypertension. Pharmacotherapy 2006, 26:1352-1357.
42. Weinmann S., Read J., Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr. Res. 2009, 113:1-11.
43. Woodward M. Epidemiology: Study Design and Data Analysis 1999, Chapman & Hall/CRC, Boca Raton, FL.